Nivisnebart

Highest phase reached
Phase 2
www.ebi.ac.uk
Drug type
Antibody
www.ebi.ac.uk

Listing at source
Listed
Highest phase reached
Phase 2
www.ebi.ac.uk

Drug type
Antibody
www.ebi.ac.uk
Drug name
Nivisnebart
www.ebi.ac.uk

  • al 101
  • AL 101
  • gsk 4527226
  • GSK-4527226
  • gsk4527226
  • GSK4527226
  • h gamma1 heavy chain homo sapiens 1 459 vh homo sapiens ighv1 46 01 96 9 ighd ighj6 01 94 1 cdr imgt 8 8 22 26 33 51 58 97 118 1 129 homo sapiens ighg1 01 g1m17 1 ch1 k120 ch3 d12 l14 g1v40 ch2 a1 3 a1 2 s116 ch1 k120 226 130 227 hinge 1 15 228 242 ch2 l1 3 a 246 l1 2 a 247 p116 s 343 243 352 ch3 d12 368 l14 370 353 457 chs 458 459 130 459 232 214 disulfide with l kappa light chain homo sapiens 1 214 v kappa homo sapiens igkv3 15 01 100 igkj4 01 100 cdr imgt 6 3 9 27 32 50 52 89 97 1 107 homo sapiens igkc 01 100 km3 a45 1 v101 c kappa a45 1 153 v101 191 108 214 dimer 238 238 241 241 bisdisulfide produced in chinese hamster ovary cho cells glycoform alfa
  • H-gamma1 heavy chain Homo sapiens (1-459) [VH (Homo sapiens IGHV1-46*01 (96.9%) -(IGHD) -IGHJ6*01 (94.1%), CDR-IMGT [8.8.22] (26-33.51-58.97-118)) (1-129) -Homo sapiens IGHG1*01, G1m17,1 CH1 K120, CH3 D12, L14, G1v40 CH2 A1.3, A1.2, S116 (CH1 K120 (226) (130-227), hinge 1-15 (228-242), CH2 L1.3>A (246), L1.2>A (247), P116>S (343) (243-352), CH3 D12 (368), L14 (370) (353-457), CHS (458-459)) (130-459)], (232-214')-disulfide with L-kappa light chain Homo sapiens (1'-214') [V-KAPPA (Homo sapiens IGKV3-15*01 (100%) -IGKJ4*01 (100%), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (153'), V101 (191')) (108'-214')]; dimer (238-238'':241-241'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa
  • Immunoglobulin G1 [246-alanine,247-alanine,343-serine], anti-(human sortilin) (recombinant human monoclonal S-15-10-7 allotype G1m17(1) γ1-chain), disulfide with recombinant human monoclonal S-15-10-7 κ-chain, dimer
  • immunoglobulin g1 246 alanine 247 alanine 343 serine anti human sortilin recombinant human monoclonal s 15 10 7 allotype g1m17 1 γ1 chain disulfide with recombinant human monoclonal s 15 10 7 κ chain dimer
  • immunoglobulin g1 kappa anti homo sapiens sort1 sortilin 1 gp95 nt3 homo sapiens monoclonal antibody
  • immunoglobulin G1-kappa, anti-[Homo sapiens SORT1 (sortilin 1, Gp95, NT3)], Homo sapiens monoclonal antibody;
  • nivisnebart
  • Nivisnebart
  • nivisnebart [INN]
  • NIVISNEBART [USAN]
  • nivisnebart inn
  • nivisnebart usan
  • s15 10 7
  • S15-10-7

CAS registry numbers
  • 2923556-87-8
ChEMBL ID
CHEMBL6068272
www.ebi.ac.uk
FDA ingredient codes (UNII)
  • YRU8TD2FZD

First in class
No
Orphan designation
No

Pharmacology name
nivisnebart
Type
Antibody
Drug name stem
-bart

Mechanisms of action

  • Action
    Antagonist
    Action type
    Antagonist
    Target
    sortilin 1
    Gene symbol
    SORT1
    Protein identifier
    Q99523

Prodrug
No
Chirality
Single enantiomer
Inorganic
No
Natural product
No

  • Component
    Light chain
    Type
    Protein
    Sequence
    EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGRAPRLLIYGASTRATGIPARESGSGSGTEETLTISSLQSEDEAVYYCQQARLGPWTEGGGTKVEIKRTVAAPSVEIEPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSENRGEC
  • Component
    Heavy chain
    Type
    Protein
    Sequence
    QVQLVQSGAEVKKPGASVKVSCKASGYTETKYYMSWVRQAPGQGLEWMGIINPIGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSIRSEDTAVYYCARDPSGIALAGPASRGYQGMDVWGQGTTVTVSSASTKGPSVEPLAPSSKSTSGGTAALGCLVKDYEPEPVTVSWNSGALTSGVHTEPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKATPASIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGEYPSDIAVEWESNGQPENNYKTTPPVLDSDGSEFLYSKLTVDKSRWQQGNVESCSVMHEALHNHYTQKSLSLSPGK
  • Component
    Disulfide bridges
    Sequence
    22-96 $ 22''-96'' $ 23'-88' $ 23'''-88''' $ 134'-194' $ 134'''-194''' $ 156-212 $ 156''-212'' $ 232-214 $ 232''-214' $ 238-238'' $ 241-241'' $ 273-333 $ 273''-333'' $ 379-437 $ 379''-437''
  • Component
    Glycosylation sites (N)
    Sequence
    309 $ 309''

Related records

Trials (2)